The FDA has approved the polypill Exforge HCT for treating hypertension. Novartis Pharmaceuticals' Exforge HCT includes the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan and the diuretic hydrochlorothiazide. FDA said the drug can be substituted for patients already on all three individual drugs or given to patients who don't fully respond to medications in two of three drug classes involved in the therapy.

Related Summaries